Navigation Links
Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
Date:1/28/2011

PITTSBURGH, Jan. 28, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nisoldipine Extended-release (ER) Tablets, 8.5 mg, 17 mg, 25.5 mg and 34 mg. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Nisoldipine ER Tablets and has been awarded 180 days of marketing exclusivity.

Nisoldipine ER Tablets are the generic version of Shionogi Pharma's Sular® Tablets, a treatment for hypertension. Nisoldipine ER Tablets had U.S. sales of approximately $103 million for the 12 months ending Sept. 30, 2010, according to IMS Health. Product from Mylan is available for shipment.

Currently, Mylan has 168 ANDAs pending FDA approval representing $97.7 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $24.2 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
2. Mylan Announces Lipitor® Settlement Agreement
3. Mylan Announces Caduet® Settlement Agreement
4. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
5. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
6. Mylan Receives Approval for Generic Version of Precose® Tablets
7. Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq
8. Mylans Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe
9. Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT®
10. Mylan Receives Approval for Generic Version of Adalat® CC Tablets
11. Mylan Announces the Conversion of its Preferred Stock into Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 Under ... Chinese pharmaceutical packaging market size increased year by ... From 2017 to 2021, the market size will ... is expected to outnumber RMB140 billion in 2021, ... the rapid development of biological agents and supporting ...
(Date:3/22/2017)... Pennsylvania , 22. März 2017 /PRNewswire/ ... unabhängige und weltweit tätige Anbieter von Produkten ... heute den Erwerb von EPL Archives Inc. ... Stoffe, der Kunden im kompletten Zyklus regulierter ... Verwahrung von Proben, Speicherung von Dokumenten und ...
(Date:3/22/2017)... 22, 2017  Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced the latest line-up ... 2017 is a day full of presentations, posters, ... (QSP) community. The focus is to learn about ... accelerating drug research and development. The ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest ... centric payment system, to expand its focus on patient care by providing an ... , “At Ogden Clinic, we are working to become a different type ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider of circulating ... in circulating tumor cells using microfluidic western blotting” in Nature Communications on March ... technology to capture CTCs and a microfluidic single-CTC resolution Western blot from ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... providing insurance assistance, financial planning, and related services to residents of the region, ... promote awareness of threatened species and wild lands. , Endangered Species International is ...
(Date:3/22/2017)... ... March 22, 2017 , ... Soriant recognizes that ... bypasses that. Healthcare facilities across the country are always forced to focus ... and hospitals, across the country, an efficient and quick way to estimate savings ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... that its digital marketing solutions have enabled Children’s Hospital of The King’s Daughters ... , Recognizing the value of a digital marketing approach, the 206-bed pediatric ...
Breaking Medicine News(10 mins):